Nanomaterial-Mediated Nucleic Acid Delivery for Pancreatic Cancer Therapeutics
Urmica Nandy1, Abul Kalam Azad Mandal1, Pranav2
1School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore Campus, Vellore 632014, India.
Abstract:
Pancreatic cancer (PC), one of the most aggressive and lethal malignancies, remains an imminent threat to human health despite enormous advancements in cancer research. Traditional therapeutic approaches are unable to significantly enhance the life expectancy of PC patients due to limitations such as lower targetability, recurrence of cancerous tumors, and side effects on healthy cells. Nucleic acid therapeutics (NATs) offer a promising alternative against traditional approaches due to their ability to target and modify genetic pathways involved in PC progression, thus providing precision treatment. However, their efficient transportation to cancerous cells and tissues is still a major obstacle. Because of the high biocompatibility, tunable physicochemical characteristics, surface functionalization potential, and scalable manufacturing potential, nanomaterials have established themselves as a frontrunner as a delivery carrier against different diseases. Considering this, different nanocarriers were explored as a vehicle for anticancer therapeutics, especially to deliver therapeutic drugs, NATs, etc., and also provided a shield against enzymatic and chemical degradation in the bloodstream while promoting tumor-specific accumulation and targetability. Pertaining to this, in the current review, we have systematically discussed the development of nanomaterial-based NATs delivery systems for the delivery of nucleic acids like siRNA, miRNA, mRNA, saRNA, pDNA, CRISPR-Cas9 guide RNA, and other nucleic acids against PC, with an emphasis on their benefits, drawbacks, and translational potential. We also highlighted and compared the preclinical assessment of nanomaterial-mediated NATs delivery in PC therapy in wild-type and drug-resistant PC cells and discussed NATs delivery in two-dimensional (2D) and three-dimensional (3D) cell culture models alongside in vivo and clinical studies. Additionally, we also explored the possibilities of the 3D cell culture model's advantage over traditional 2D cell cultures and their relevance to in vivo systems, especially in facilitating NATs delivery and clinical translation possibilities, and paved the way for future research and clinical applications toward precision medicine.
Insights
Nanomaterials offer a promising delivery system for nucleic acid therapeutics (NATs) to combat aggressive pancreatic cancer (PC). This review explores nanomaterial-based NAT delivery systems, highlighting their potential for precision medicine in PC treatment.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Pancreatic cancer (PC) is a lethal malignancy with limited treatment options, necessitating novel therapeutic strategies.
- Traditional therapies face challenges in targetability, recurrence, and side effects, driving the need for precision medicine approaches.
- Nucleic acid therapeutics (NATs) show promise for PC by targeting genetic pathways, but efficient delivery remains a hurdle.
Purpose of the Study:
- To systematically review the development and application of nanomaterial-based delivery systems for NATs in pancreatic cancer therapy.
- To evaluate the benefits, drawbacks, and translational potential of various nanocarriers for NAT delivery against PC.
- To compare the efficacy of nanomaterial-mediated NAT delivery in different preclinical models, including 2D and 3D cell cultures and in vivo studies.
Main Methods:
- Comprehensive literature review of nanomaterial-based nucleic acid therapeutics for pancreatic cancer.
- Analysis of preclinical data comparing NAT delivery in wild-type and drug-resistant PC cells.
- Evaluation of NAT delivery in 2D and 3D cell culture models, alongside in vivo and clinical studies.
Main Results:
- Nanomaterials demonstrate high biocompatibility and tunable properties, making them effective carriers for NATs.
- Nanocarriers enhance tumor-specific accumulation and protect NATs from degradation, improving targetability.
- Preclinical assessments show promise for nanomaterial-mediated NAT delivery in various PC models, with 3D cultures offering improved relevance to in vivo systems.
Conclusions:
- Nanomaterial-based NAT delivery systems represent a significant advancement in precision medicine for pancreatic cancer.
- Further research into 3D cell culture models can bridge the gap between preclinical findings and clinical translation.
- Optimized nanocarrier design and delivery strategies are crucial for overcoming current limitations and advancing NATs for PC treatment.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
